Form 4: Altimmune CBO Exercises RSUs, Covers Taxes

Altimmune's Chief Business Officer, Raymond M. Jordt, converted Restricted Stock Units into common stock and sold a portion to cover tax obligations.

Summary

• Raymond M. Jordt, Chief Business Officer of Altimmune, Inc., engaged in transactions involving the company's common stock on January 1, 2026.
• Jordt acquired 9,375 shares of common stock through the vesting and conversion of Restricted Stock Units (RSUs).
• Concurrently, 2,475 shares were disposed of at a price of $3.61 per share to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Jordt directly beneficially owns 43,170 shares of common stock.
• The RSUs vest over four years, with 25% vesting on January 1, 2024, and the remainder in equal annual installments for the subsequent three years.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive as it reflects routine executive compensation and continued insider ownership, albeit with a tax-related sale. It doesn't indicate any new operational news or significant strategic shifts.

Positives

• The vesting of Restricted Stock Units indicates continued long-term incentive alignment between the Chief Business Officer and shareholder interests.
• The conversion of RSUs into common stock increases the officer's direct ownership of company shares.

Negatives

• A portion of the vested shares (2,475 shares) was sold to cover tax obligations, which represents a reduction in direct shareholding.

Future Outlook

The filing indicates a pre-scheduled vesting of Restricted Stock Units, suggesting a continuation of the company's long-term equity compensation plan for its Chief Business Officer.

Industry Context

This Form 4 filing is a routine disclosure of insider equity transactions, common across all publicly traded companies, particularly in the biotechnology sector where equity compensation is a significant component of executive remuneration. It does not provide specific insights into Altimmune's operational performance or broader industry trends beyond the standard practice of executive compensation.

Comparison to Industry Standards

• The RSU vesting and subsequent tax-related share disposition are standard practices for executive compensation in the U.S. public markets, particularly within the biotech industry.
• The vesting schedule over four years is typical for aligning executive incentives with long-term company performance.
• No specific comparable companies, projects, or results are mentioned in this regulatory filing.

Stakeholder Impact

• Shareholders: The transactions represent a routine change in insider ownership, with a slight reduction due to tax-related sales, which is a common occurrence and generally not indicative of a change in management's confidence.
• Employees: The RSU vesting demonstrates the company's ongoing equity compensation practices for its executives.

Next Steps

• Future annual installments of RSU vesting are expected on subsequent January 1st dates, as per the four-year vesting schedule.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax-related sales). It does not provide new material information regarding the company's financial performance, strategic direction, or operational outlook that would warrant a change in investment recommendation. The transactions are expected and do not signal a significant positive or negative shift in the company's fundamentals or management's confidence.

Keywords

Altimmune, ALT, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Common Stock, Chief Business Officer, Raymond M. Jordt, Equity Compensation